Year-end Sale % OFF 
Abstract
Hypertension affects 41% of male and 31% of female adults in Belgium; 13% of these are believed to be refractory to standard hypertension treatment, defined as uncontrolled hypertension under ≥ 3 different classes of antihypertensive drugs. Surgical renal denervation has been used in the past, but due to significant side effects it was abandoned. Catheter-based renal denervation (RDN) is a novel, minimally invasive therapy for treatment-resistant hypertension. The results of the Symplicity HTN-2 randomised trial (Esler, 2010) were used to conduct cost-effectiveness and cost-utility analyses comparing RDN to current standard of care (SoC) for treatment of refractory hypertension in Belgium. Background
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
